月份: 2026 年 3 月

SINGAPORE – March 18, 2026 – (SeaPRwire) – AdsDrama, a digital platform focused on short drama content and online advertising, has introduced an ecosystem designed to integrate content distribution, advertising services, and user participation. The launch comes as short-form video continues to expand globally, shaping how content is consumed and monetized across digital channels. What Is AdsDrama? AdsDrama (https://www.adsdrama.com) is a platform centered on short drama marketing and digital advertising monetization. It connects content creators, advertisers, and users through a structured system intended to support content distribution and advertising delivery. Unlike traditional content platforms where users primarily consume media, AdsDrama incorporates a participation-based model. Users can engage with certain platform functions related to content promotion and advertising processes. The platform operates through a structured framework designed to simplify user access and participation. User Onboarding New users can register and access an introductory interface that presents the platform’s core features, including its advertising workflows and operational structure. This step is intended to provide a general understanding of how the platform functions. Participation Through Structured Levels After onboarding, users may choose to access different participation levels. Each level provides access to specific platform features, which may include: Defined activity parameters Access to advertising-related tasks System-based allocation of activities The platform indicates that certain processes are managed through internal systems that handle distribution and performance tracking. Automated Advertising System AdsDrama utilizes a data-driven system to distribute short drama content across various digital channels, including: Social media platforms Short video networks Other online content distribution channels The platform states that it applies audience targeting and traffic allocation tools to support content visibility. Revenue Model According to AdsDrama, the platform incorporates multiple revenue streams as part of its business model: Online advertising revenue derived from ad placements and traffic distribution Content monetization, including paid access to selected short drama content Brand collaborations, such as sponsored content and integrations IP commercialization through licensing and content expansion Technology services related to advertising delivery and data optimization The company states that this diversified structure is intended to support ongoing platform development. Key Features of AdsDrama Data-Driven Optimization AdsDrama reports that it uses analytics and performance tracking tools to monitor advertising campaigns and refine delivery strategies. Structured Financial System The platform describes a multi-layer account system designed to manage user balances, which may include: Available balances Processing stages Pending allocations This structure is intended to support internal accounting processes and system organization. Standardized Withdrawal Mechanism AdsDrama indicates that it applies standardized procedures for withdrawals within its operational framework, aiming to streamline processing and reduce administrative complexity. Why AdsDrama Is Growing Industry trends may help explain the emergence of platforms such as AdsDrama: Growth of short-form content, as short video and serialized formats continue to attract broad audiences Expansion of digital advertising, with businesses increasing spending on online channels Gradual shift toward participation-based models, where users engage beyond passive content consumption Is AdsDrama Worth Exploring? AdsDrama may be relevant to individuals and organizations interested in: Digital advertising platforms Content distribution models Emerging forms of online engagement As with any platform, users are encouraged to review publicly available information and consider potential risks before engaging. AdsDrama represents an approach that combines short-form content with digital advertising infrastructure and user-facing features. As the digital media landscape continues to evolve, platforms of this kind reflect ongoing experimentation in content distribution and monetization models. Media contact Brand: AdsDrama LTD Contact: Media team Website: https://www.adsdrama.com

Cyprus, EU, Mar 16, 2026 - March 16, 2026 - (SeaPRwire) - FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor's approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client's internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner's IBAN account infrastructure. During the second week the team activated card issuing and configured the platform's connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective "The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. "Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website:  https://www.finharbor.com/

Cyprus, EU, Mar 16, 2026 - March 16, 2026 - (SeaPRwire) - FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor's approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client's internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner's IBAN account infrastructure. During the second week the team activated card issuing and configured the platform's connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective "The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. "Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website:  https://www.finharbor.com/

Nicosia, Cyprus – March 17, 2026 – (SeaPRwire) – FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor’s approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client’s internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner’s IBAN account infrastructure. During the second week the team activated card issuing and configured the platform’s connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective “The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. “Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website:  https://www.finharbor.com/

The Singapore-headquartered platform helps brands improve content reach and conversion in the era of short-form video and interest-based e-commerce. SINGAPORE – March 16, 2026 – (SeaPRwire) – As short-form video continues to reshape how information spreads and how consumers engage with brands, efficient collaboration between brands and creators has become increasingly important. Hello IP was built to address this need. Hello IP is a content distribution platform focused on social and interest-based e-commerce. By enabling brands to upload ready-made video content and distribute it through local creators across social platforms, Hello IP helps reduce the complexity of traditional creator collaborations, improve campaign efficiency, and create more sustainable monetization opportunities for creators. Under traditional creator marketing models, brands often face lengthy workflows that include influencer sourcing, repeated negotiation, contract signing, sample shipping, content review, and payment settlement. These processes can be slow, costly, and difficult to manage, especially in cross-border campaigns where shipping risks, inconsistent content quality, and uncertain outcomes remain common challenges. Hello IP offers a more efficient alternative. After brands upload content to the platform, creators can select tasks that match their style, audience, and interests, then distribute that content through their own channels. This model helps brands gain more localized and authentic exposure while allowing creators to earn performance-based rewards. To support faster market expansion, Hello IP has developed its core distribution system, Viral Engine, which combines creator distribution, influencer collaboration, advertising support, and cross-market strategies. The platform is currently active in mature TikTok e-commerce markets across Southeast Asia, the United Kingdom, and the United States, with content able to reach targeted creator communities in as little as 24 hours. For creators, Hello IP provides access to daily brand campaigns across categories such as beauty, mobile apps, e-commerce, and gaming. By lowering collaboration barriers and simplifying campaign participation, the platform helps creators unlock more stable income opportunities and build long-term commercial value. Mao Jianfeng, Founder of Hello IP, said, “In today’s creator economy, brands need content distribution models that are more efficient, scalable, and closely connected to local markets. Hello IP aims to build a smoother connection between brands and creators so that both sides can grow together.” As digital marketing enters a new phase, Hello IP’s connector model is creating a more efficient and inclusive path forward for the content ecosystem. About Hello IP Hello IP is one of ET CUBE’s core business pillars in the creator economy, focused on content distribution for social and interest-based e-commerce. Headquartered in Singapore, the platform connects brand content with local creator networks to help brands achieve faster, more authentic distribution and stronger conversion opportunities across key international markets. Media Contact Brand Name: Hello IP Website: https://www.helloipmcn.com

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients. The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance. More information about Desidustat Tablets and Renal Anaemia As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders. There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia. Desidustat Tablets have been approved for marketing in India. CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020. The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6 2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015 3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025) 4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012 CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order. As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients. The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026). Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster. As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2]. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval. The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. China Insights Consultancy’s industrial report  2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.  3. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 4. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.